NanoEcho’s clinical dose confirmation study has achieved its primary objectives according to the study’s design. This is a crucial milestone, indicating that the study has established an appropriate dose of the nanoparticle NEP-1 (ferumoxtran) as well as the time interval for the subsequent imaging examination. The study is the first clinical trial with NanoEcho’s imaging system, which is based on the magnetomotor ultrasound method – developed through years of research at Lund University.
“It is a great success that we have used our system for the first time in a clinical environment with study participants. We have achieved the primary objectives of the study, which is a significant milestone. The collected clinical data provides us with valuable insights and now allows us to optimize our system for clinical use,” comments Linda Persson, CEO of NanoEcho.
Read more in our press release! (in Swedish)
